Skip to main
AVGR
AVGR logo

Avinger (AVGR) Stock Forecast & Price Target

Avinger (AVGR) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 17%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Avinger Inc. is poised for significant revenue growth due to its planned expansion of the sales and clinical support team by over 25% in the fourth quarter, with expectations for further increase in the coming year. Successful commercialization of new products and anticipated FDA registration are expected to enhance gross margins starting in late 2025 or early 2026, particularly through collaboration with Zylox-Tonbridge. The combination of these factors, alongside strong market adoption of the Tigereye ST device, positions Avinger favorably for meaningful revenue growth in the short to mid-term.

Bears say

Avinger Inc has faced challenges in revenue growth, primarily due to underperformance in product sales within its core market of peripheral artery disease, where the majority of its income is generated. Additionally, the company has encountered increased operational costs and inefficiencies, which have negatively impacted its profitability and financial stability. Furthermore, the competitive landscape within the medical device industry, coupled with regulatory hurdles, presents ongoing risks that could hinder future performance and market expansion.

Avinger (AVGR) has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Avinger and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Avinger (AVGR) Forecast

Analysts have given Avinger (AVGR) a Buy based on their latest research and market trends.

According to 6 analysts, Avinger (AVGR) has a Buy consensus rating as of Aug 11, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Avinger (AVGR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.